What we have to learn from day one when we design these AI applications, is that pathology has to come with us. We cannot just design a network as computer scientists and then go to the pathologists just when we need to validate it. The pathologist has to be with us from the start.
Tribun Health: In response to a call for tenders, Tribun Health had to undergo numerous evaluations and a rating system before joining the UniHA network in digital pathology.Paris, France, November 29th, 2022 – UniHA is a large cooperative of French public hospital purchasers whose mission is to select the best providers in order to bring citizens the most effective treatments available, the best quality of hospital services and to maintain equal access to care.Tribun Health, the European leader in software development for digital pathology, is pleased to have won the third UniHA lot consisting of an Image Management System (IMS) for the complete integration of imaging in anatomo-cytopathology departments for institutions with at least seven sites. In acquiring this contract, Tribun Health has demonstrated its leadership and ability to meet the needs of large hospitals and multi-site groups. This package includes all the tools, licenses, maintenance, and support services that will enable hospitals to make a successful digital transition in the best possible time and conditions. Tribun Health will provide personalized, high-quality follow-up, with customer satisfaction as its priority. This innovative solution meets the needs of pathology laboratories by providing increased clinical confidence, ultimate flexibility, highly scalable and enhanced productivity. ”As an IMS supplier, we are delighted to be part of this purchasing group to meet the needs of large hospital sites. It’s also a way to showcase our products and our support team, which stood out in a bidding environment thanks to our ability to innovate, especially in terms of AI integration” says Ludovic d’Apréa, Chief Customer Officer of Tribun Health.To win this third contract and establish this long-standing partnership with UniHA, Tribun Health had to meet several evaluation criteria concerning the technical value of its IMS, CaloPix, such as: Technical questionnaires regarding IMS, RACI, failures, maintenance service and innovation prospects with a panel of experts, followed by a hands-on demonstration with the tool.About UniHA:The UniHA health cooperation group is the leading cooperative purchasing network for French public hospitals. It is also the leading French public purchaser, with over €6.2 billion in purchases and a volume of gains on purchases of €150 million by 2022. UniHA currently brings together more than 1,200 hospitals and 120 regional hospital groups (GHT). UniHA covers 16 purchasing families, which meet the main needs of hospitals, and can serve all public health institutions. With its 130 employees and its supplier companies, UniHA aims to make purchasing a global performance lever to support the transformation and innovation of the healthcare system, positioning itself as a strategic player in the healthcare sector.About Tribun Health:Tribun Health empowers confident decisions. The Paris based, privately held company addresses a significant, fast-growing, and unmet need for expert end-to-end pathology department digitalization. Tribun Health is a pioneer in digital pathology workflow solutions with image acquisition (Macro), image storage/organization, web-based image management system (IMS), image analysis using AI-powered deep and machine learning algorithms, remote case sharing with peer review and reporting. Tribun Health’s award-winning core platform, CaloPix, is considered the industry leader winning the Best in Klas 2022 award for the most successful digital pathology provider in Europe. Tribun Health’s extensive, decade long expertise drives confidence for laboratories looking for a seamless transition to a digital pathology platform.UniHA Contact:Pierre Tromas, Buyer+33 6 26 74 38 08Pierre.tromas.uniha(@)chu-poitiers.frTribun Health Contact:Lorine Marcoux, Marketing Programs Manager+33 1 89 20 38 53lmarcoux(@)tribun.healthSOURCE: Tribun Health
With the recent launch of a product to evaluate artificial intelligence (AI) models for accuracy and susceptibility to bias, Mayo Clinic Platform is accelerating adoption of data-driven innovation in clinical practice.Mayo Clinic Platform_Validate confirms the efficacy and credibility of newly developed algorithms and ensures they are fit for their intended purpose. Validate is one of the first products in the industry that provides a bias, specificity and sensitivity report for AI models. It joins Mayo Clinic Platform_Discover, which offers AI developers access to curated, deidentified electronic health data in a secure, privacy-protected environment, along with the tools for discovery, analysis and training, to help solve some of patients’ most pressing needs.In nearly three years since it began, Mayo Clinic Platform has built an ecosystem that orchestrates multiple collaborations with health technology innovators, enabling discoveries across the health care sector.“Our platform aims to improve patient care by fundamentally changing the nature of health care delivery,” says John Halamka, M.D., president of Mayo Clinic Platform. “By addressing the countless deficiencies and inequities built into the current system, we are ushering in a new era of democratization of health care, where accessible, compassionate and personalized care is available to everyone, everywhere.”Much of the skepticism around AI and machine learning is focused on the poor quality of evidence supporting some algorithms. Biased algorithms can lead to incorrect diagnoses and other serious risks for patients.With the new Mayo Clinic Platform_Validate product, algorithms are measured for model bias observed in categories from age to ethnicity. Similar to the way a nutrition label on foods and beverages details the products’ ingredients, Validate reports how an AI algorithm performs under different constraints, including racial, gender and socioeconomic demographics. Clinicians can trust that AI models were evaluated by an independent third-party source. This transparency will help reduce bias and achieve equity in health care.Mayo Clinic Platform_Discover helps health care innovators solve some of the most complex clinical challenges by offering clinical insights from Mayo Clinic Platform’s extensive deidentified electronic health data across a range of disease and therapeutic areas.The deidentified data are in a secure environment that enables companies to develop algorithm models, but these data never leave the Mayo Clinic cloud computing environment.Looking at the numbers offers a sense of the depth of real-world data AI developers can access with Discover:10 million patients, spanning across geographies and therapeutic areas644 million clinical notes from 5.3 million patients, collected over 40 years3 million echocardiograms, showing the heart muscle in action111 million electrocardiograms, or ECGs, showing electrical activity of the heart1.2 billion lab test results9 billion pathology reports595 million diagnoses and 771 million proceduresDiscover also offers augmented-curation technology to analyze real-world data from health records to accelerate clinical decision support.Just as an art or library collection is curated so artists’ or authors’ works are assembled, organized, exhibited and stored to allow access and interpretation, so too does data curation enable scientists to access secure and searchable indexes that make clear where and how data are generated and stored. Data are from diverse sources and can be integrated in repositories, authenticated and archived.Companies such as BD (Becton, Dickinson and Company) and K Health are using Discover’s data to improve patient care. BD, one of the largest global medical technology companies, is generating real-world evidence related to BD products. K Health, an AI-powered clinical health care company, is using Discover to reduce the time between the diagnosis and treatment of hypertension.As Discover continues to grow and evolve, a new family of applications is being offered to help customers filter, explore and analyze the data from multiple vantage points.Continuing to growMayo Clinic Platform’s products like Validate and Discover are core building blocks of one of the first comprehensive multisided platforms in health care, facilitating interactions among multiple producers and users.“Coordination of care across labs, pharmacies, clinics, hospitals and home care settings requires platform thinking and a new attitude toward privacy-protected information sharing,” says Maneesh Goyal, chief operating officer, Mayo Clinic Platform. “Using data-derived insights and knowledge, the platform model gives the opportunity to improve patient care beyond our walls.”The ecosystem has grown to include new data network partners and innovators tackling a range of health care problems.Mayo Clinic and Mercy, based in St. Louis, recently launched a 10-year collaboration agreement, the first of its kind between two large health care systems to use the most current data science and years of deidentified patient outcomes to find diseases earlier and start patients on paths to better health more quickly. Mercy’s and Mayo’s different populations and geographic locations will improve accuracy, reduce model bias and create more diverse, and therefore stronger, treatment recommendations for patients.Through the Mayo Clinic Platform_Accelerate program, early-stage health tech startups are able to develop and validate their AI-driven health care products, advancing innovative ideas from the proof-of-concept stage to clinical readiness.“Using data, early prediction and detection of diseases can become a reality that transforms health care for people everywhere,” Dr. Halamka says. “We feel Mayo Clinic Platform is uniquely positioned to make this ambitious goal a reality because we are founded on Mayo Clinic’s dedication to patient-centered care, treatment of rare and complex cases, exceptional outcomes, and world-class research.”###About Mayo Clinic PlatformFounded on Mayo Clinic’s dedication to patient-centered care, Mayo Clinic Platform. enables new knowledge, new solutions and new technologies through collaborations with health technology innovators to create a healthier world. To learn more, visit Mayo Clinic Platform.About Mayo ClinicMayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.Media contact:SOURCE: Mayo Clinic News Network
The rate of clinical adoption of digital pathology for diagnosis has increased drastically over the past few years. Despite numerous studies to validate the performance of whole slide imaging (WSI) in facilitating accurate and reliable diagnosis, limited efforts have been made to systematically compare the diagnostic performance of digital pathology to that of light microscopy.
EVIDENT and Ultivue: Collaboration provides a convenient, fast tool for multiplexed immunofluorescence imaging in translational studiesWALTHAM and CAMBRIDGE, Mass., (Nov. 7, 2022)—Evident Corporation, a premier manufacturer of life science imaging systems, and Ultivue, Inc., an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies, announced a collaborative agreement to promote whole slide imaging using multiplexed immunofluorescence (mIF) assays to advance translational research in the Americas.Combining Ultivue’s mIF assays with the Olympus SLIDEVIEW™ VS200 research slide scanner provides a convenient, fast tool for whole slide mIF imaging in translational studies for researchers in academia, biotech, pharma and contract research organizations in the Americas. The collaboration builds on their existing partnership to meet the scientific community’s increasing need for fluorescent multiplexing.Ultivue develops unique solutions for mIF applications, imaging and spatial phenomics. Its proprietary InSituPlex® technology enabling improved signal-to-noise data is designed for fast and comprehensive exploration of up to 12 biologically relevant targets in one tissue slide, with same-slide hematoxylin and eosin (H) analysis in tissue samples. This technology combines the power of computational pathology and spatial biology to guide translational science in immuno-oncology.Evident Corporation, a wholly owned subsidiary of Olympus Corporation, manufacturers leading-edge life science microscopes that support a broad range of academic and clinical research areas, pathology diagnostic services and the growing demand for novel drug discovery. The Olympus VS200 slide scanner has advanced the field of whole slide imaging with high-quality optics, fast scanning and flexible imaging options that include a robust solution for fluorescent multiplexing.“We are excited to enhance our relationship with Evident to further optimize the integration of Ultivue assays on the SLIDEVIEW VS200 research slide scanner. We jointly enable highly efficient workflows to drive adoption of tissue multiplexing on larger cohorts,” said Florian Leiss, PhD, the Vice President of Product Strategy and Corporate Development at Ultivue.“We are delighted to continue to collaborate with Ultivue to provide a total solution for multiplexing,” said Lee Wagstaff, the Vice President of Life Science Sales and Marketing at Evident Americas. “With Ultivue’s assays and our slide scanning technology, we can provide a complete workflow solution for our customers that enables them to work more efficiently.”About EVIDENTAt Evident, we are guided by the scientific spirit—innovation and exploration are at the heart of what we do. Committed to making people’s lives healthier, safer and more fulfilling, we support our customers with solutions that solve their challenges and advance their work, whether it is researching medical breakthroughs, inspecting infrastructure, or exposing hidden toxins in consumer products.Evident Life Science empowers scientists and researchers through collaboration and cutting-edge life science solutions. Dedicated to meeting the challenges and supporting the evolving needs of its customers, Evident Life Science advances a comprehensive range of microscopes for pathology, hematology, IVF, and other clinical applications as well as for research and education.For more information, EvidentScientific.com.About UltivueUltivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex® technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions coupled with our scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs.Learn more at Ultivue.com.Media Contact:Hilary Banda(781) 41******************@***************ic.comEvident and the Evident logo are trademarks of Evident Corporation or its subsidiaries.SOURCE: EVIDENT
For many studies that have been done to date, it is difficult to gain access to and reproduce the AI models that are referenced in the literature," he said. "By creating and sharing FAIR AI models, we can reduce the amount of duplication of effort and share best practices for how to use these models to enable great science."
Join Dr. Arnaud Gauthier in a LIVE webcast as he transfers his expert insight on the implementation of Digital Pathology from his experience working at the Institut Curie.
Learn how SPIAT can be applied to HALO data, understand how cell co-localization can be measured with SPIAT.
Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications, today announced it has entered into a multi-stage research agreement with the University Medical Center (UMC) Utrecht in the Netherlands. UMC Utrecht will deploy Paige AI applications for routine clinical use and conduct a clinical health economics study to support the adoption and reimbursement of AI applications in pathology.The prospective CONFIDENT clinical study will evaluate the performance of the Paige Prostate Suite in a real-world setting. A minimum of 90 patients are expected to be enrolled in CONFIDENT and will receive their standard-of-care diagnosis. Pathologists will use Paige Prostate as part of their existing workflow. The primary endpoint is the impact on the ordering and use of immunohistochemistry (IHC) stains in a prospective clinical setting. CONFIDENT will also evaluate the efficiency of diagnoses when assisted by Paige Prostate. UMC Utrecht and Paige have already begun validation of the software and pathologist validation in addition to aligning with data governance requirements to enable prospective deployment.Paige Prostate Suite, which draws pathologists’ attention to areas of tissue suspicious of harboring cancer, is comprised of Paige Prostate Detect, Paige Prostate Grade & Quantify, and Paige Prostate Perineural Invasion. Paige Prostate Detect is the only FDA approved AI-powered pathology product available for in vitro diagnostic use.“UMC Utrecht and Paige share a vision to improve outcomes for patients with cancer and health systems by leveraging quality AI solutions that help standardize the cancer diagnosis process,” said Andy Moye, Ph.D., Chief Executive Officer at Paige. “Specifically, this collaboration builds on pioneering work from Utrecht which demonstrated large systemic variability in Gleason scoring of prostate biopsies nationwide in the Netherlands. Paige’s AI software can help overcome these diagnostic challenges. This partnership marks another significant milestone in our efforts to modernize and improve the process of cancer diagnosis globally.”In early 2016, UMC Utrecht became the first hospital in the Netherlands to digitize its entire pathology workflow. UMC Utrecht currently employs the Sectra Digital Pathology Solution, a vendor-neutral solution for primary diagnostics in its pathology operations. Integration of Paige applications with the Sectra solution is currently underway, and UMC Utrecht may perform additional validation studies using the combined solution.“As one the earliest adopters of digital pathology workflows, we must continuously demonstrate how these tools can ultimately benefit pathologists, patients and the economics which drive sustainable clinical practices,” said Paul van Diest, M.D., Ph.D., Professor and Head of Pathology at UMC Utrecht and a member of the Scientific Advisory Board at Paige. “Having acquired the first-ever FDA clearance for a clinical AI application in pathology, Paige Prostate Detect has cleared the highest bar for quality, and this provides us with confidence as we introduce it into live patient reporting.”In addition to prostate cancer, Paige and UMC Utrecht plan to evaluate Paige Breast Lymph Node, an AI medical device software that helps pathologists detect if breast cancer has metastasized to lymph nodes, in breast lymph nodes.About PaigePaige is using the power of AI to drive a new era of cancer discovery and treatment. To improve the lives of patients with cancer, Paige has created a cloud-based platform that transforms pathologists’ workflow and increases diagnostic confidence as well as productivity, all on a global scale. Paige is the first company to receive FDA approval for a clinical AI application in digital pathology. The same Paige technology empowers pharmaceutical companies to more effectively evaluate treatment options for patients and design new biomarkers for drug development so that every patient gets precise treatment options.For additional information, please visit: https://www.paige.ai, Twitter and LinkedIn.
Deep Bio, a leading AI biotech dedicated to cancer diagnosis, and Visiopharm, a world leader in AI-powered image analysis and tissue mining for research and diagnostics, announced a strategic partnership to provide pathologists access to the latest AI-powered prostate cancer solution.AI-powered cancer diagnostics has been proving its utility not only in research, but increasingly in supporting and improving pathologists’ decisions, workflow efficiency, and diagnostic precision. Deep Bio’s deep learning-based CE-IVDD prostate cancer diagnosis support software, DeepDx® Prostate, empowers pathologists by identifying cancerous areas and grading their severity providing a Gleason scoring.With this collaboration, DeepDx® strengthens Visiopharm’s diagnostic offering to its European diagnostic customers. This application expands pathologists’ accessibility to the latest cutting-edge H&E based AI solutions for prostate cancer, which today is a large diagnostic indication that is both time– and labour intensive in diagnostic pathology labs. With its extensive AI-based image analysis solutions for multiple cancer types, Visiopharm’s platform is contributing to the global adoption of digital pathology and AI.The first phase of integration of DeepDx® into Visiopharm’s digital pathology platform has been completed. In the next phases, Visiopharm will together with Deep Bio scale up the solution as interest grows. The two companies plan to add additional AI cancer pathology solutions over time for prostate and breast, among others.The second phase of integration will aim for tighter interoperability among the platform and AI solutions, helping both companies to better promote and distribute to healthcare institutions around the world.Sun Woo Kim, CEO of Deep Bio, said:“Digital transformation in healthcare is not a new concept anymore. Pathology, which has been slow to undergo digital transformation, is fast becoming digitalized due to a diverse range of AI solutions now available for implementation and validation. Our dedication to AI for digital pathology has taken a major step forward with this collaboration and we are pleased to offer our latest technology to more labs and hospitals across the world through this opportunity. We will continue to support medical professionals to optimize their decisions which ultimately lead to the best patient care.”Michael Grunkin, CEO of Visiopharm, said:“We are seeing a lot of demand for this particular application among both our clinical research- and diagnostic customers and partners. In diagnostic workflows, this APP has the potential to support pathologists in automating time-consuming and repetitive work, while improving turnaround time and standardization. This partnership with Deep Bio is a good example of how our scanner, LIMS, and PACS agnostic platform allow our users to benefit both from our own apps and best-in-class apps from our growing partner network, to gain access to a full diagnostic menu.”About Deep BioDeep Bio Inc. is an AI healthcare company with in-house expertise in deep learning and cancer pathology. Our vision is to radically improve efficiency and accuracy of pathologic cancer diagnosis and prognosis, by equipping pathologists with deep learning-based IVD SaMDs1 (In Vitro Diagnostics Software as a Medical Device), for optimal cancer treatment decisions. Deep Bio is also actively engaged in the research space and maintains ongoing collaborations with top US medical centers. To learn more, visit www.deepbio.co.kr.DeepDx® Prostate is a clinically-validated AI for prostate core needle biopsy tissue image analysis. Whole-slide images (WSIs) of H&E-stained biopsy tissue specimens are analyzed for prostate cancer, Gleason scores and grade groups. Extensively tested at 4 US CLIA labs ( > 700k cores between 2019 and 2021), DeepDx® Prostate can alleviate the shortage of pathologists and the resultant increase in workload, while reducing diagnostic subjectivity and variabilityAbout VisiopharmVisiopharm® is a world leader in AI-driven precision pathology software. Their pioneering image analysis tools support thousands of scientists, pathologists, and image analysis experts in academic institutions, biopharmaceutical industry, and diagnostic centers. AI-based image analysis and tissue mining tools support research and drug development research worldwide, while CE-IVD APPs provide decision support. With the most advanced and sophisticated artificial intelligence and deep learning, Visiopharm delivers tissue data mining tools, precision results, and workflows.Visiopharm was founded in 2002 and is privately owned. The company operates internationally with over 750 customer accounts and countless users in more than 40 countries. The company headquarters are in Denmark’s Medicon Valley, with offices in Sweden, England, Germany, The Netherlands and United States.For enquiries: Johanne Louise BrændgaardChief Marketing Of********@********rm.comSOURCE: Visiopharm
